The move builds on a partnership established in late 2022 and includes access to AbCellera's T-cell engagers platform to develop therapeutic antibodies for tumor targets. AbCellera's T-cell ...

The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets. Under the ...

This asset-light model allows AbCellera to maintain a low cash burn while benefiting from high-profile partnerships. AbCellera’s collaborations with major players like Eli Lilly and Moderna ...

The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

AbCellera Biologics Inc. (NASDAQ ... a new industry-standard quality manufacturing facility and has established partnerships with major pharmaceutical companies, including Eli Lilly.